“The Report PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis – Global Drug Forecast and Market Analysis to 2022 – Event-Driven Update provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. – MarketResearchReports.biz”
The lupus therapeutics market is dominated by generics and GlaxoSmithKlines Benlysta is the only drug that has gained marketing approval for SLE in more than 50 years. Following Benlystas launch, patients uptake has remained low, but due to its associated high price-tag Benlysta has managed to grow the lupus market in terms of value and is currently the top-selling drug in this market, having generated approximately $265.6m in 2014 in the seven major markets. There is high R&D activity for the development of new therapies for lupus and seven promising biological therapies have the potential to enter the SLE and LN market during the 2012-2022 forecast period. The introduction of new biologic drugs will shape the future competitive landscape and drive growth in the SLE and LN markets.
View Report At :http://www.marketresearchreports.biz/analysis/277394
Key Questions Answered
What was the impact of Benlysta on the lupus therapeutics market following its approval in 2011 and what is its future outlook in this market?
What do physicians think about Rituxan following its unsuccessful Phase III trials in LN, and how will it be used off-label in lupus during the forecast period?
What is the significance of late-phase pipeline products and how will their launch shape the future treatment landscape in SLE and LN?
What are the significant unmet needs in the SLE and LN markets?
What are the remaining opportunities in the SLE and LN markets?
The key drivers of growth for the SLE and LN markets are the increasing uptake of GlaxoSmithKlines Benlysta, the potential launch of new biologic drugs and the increasing number of prevalent cases of SLE and LN during the 2012-2022 forecast period.
R&D strategies include the development of me-too and first-in-class therapies, partnerships and acquisitions, and the development of products for LN.
The lupus therapeutics market is characterized by significant unmet needs. The most pressing unmet need is the development of new therapies that will offer potent clinical benefits, have a positive safety profile and increase the available treatment options for patients.
Download Sample copy of this Report at: http://www.marketresearchreports.biz/sample/sample/277394
Overview of SLE and LN, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options.
Annualized SLE and LN therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for ten years to 2022.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the SLE and LN therapeutics markets.
Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of mid-stage pipeline drugs.
Analysis of the current and future market competition in the global SLE and LN therapeutics markets. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Additionally a list of acquisition targets included in the pipeline product company list.
Develop business strategies by understanding the trends shaping and driving the global SLE and LN therapeutics markets.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global SLE and LN therapeutics markets in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Track drug sales in the global SLE and LN therapeutics markets from 2012-2022.
Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
1 Table of Contents
1 Table of Contents 9
1.1 List of Tables 16
1.2 List of Figures 22
2 Introduction 24
2.1 Catalyst 24
2.2 Related Reports 25
2.3 Upcoming Related Reports 25
3 Disease Overview 26
3.1 Etiology and Pathophysiology 26
3.1.1 Etiology 26
3.1.2 Pathophysiology 28
3.2 Prognosis 29
3.3 Quality of Life 29
3.4 Symptoms 30
4 Epidemiology 31
4.1 Risk Factors and Comorbidities 31
4.1.1 Women are at a higher risk of developing SLE than men 31
4.1.2 Caucasians are at lower risk of developing SLE than other ethnicities 32
4.1.3 Familial history has been associated with an increased risk of developing SLE 33
4.1.4 Certain occupational and environmental exposures trigger SLE 34
4.2 Global Trends 35
4.2.1 US 36
4.2.2 5EU 37
4.2.3 Japan 40
4.3 Forecast Methodology 40
4.4 Sources Used 42
4.4.1 US 42
4.4.2 France 44
4.4.3 Germany 44
4.4.4 Italy 44
4.4.5 Spain 45
4.4.6 UK 45
4.4.7 Japan 46
4.5 Sources Not Used 47
4.5.1 US 47
4.5.2 5EU 47
4.5.3 Japan 48
4.6 Forecast Assumptions and Methods 48
4.6.1 US 49
4.6.2 5EU 49
4.6.3 Japan 52
4.7 Epidemiological Forecast of SLE (2012-2022) 53
4.7.1 Diagnosed Prevalent Cases of SLE 53
4.7.2 Age-Specific Prevalent Cases of SLE 55
4.7.3 Sex-Specific Prevalent Cases of Diagnosed SLE 57
4.7.4 Age-Standardized Prevalence of SLE 58
4.7.5 Diagnosed Prevalent Cases of LN 59
4.7.6 Prevalent Cases of LN, Segmented by Class 61
4.8 Discussion 63
4.8.1 Conclusions on Epidemiology Trends 63
Follow us on LinkedIn: https://www.linkedin.com/company/marketresearchreports-biz
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
90 Sate Street, Suite 700
Albany, NY 12207